Beyond Meat (BYND) closed at $56.54 in the latest trading session, marking a -0.04% move from the prior day.
Clorox (CLX) Q2 results are likely to reflect impacts of unfavorable price mix, lower shipments, and elevated logistics and commodity costs. Its IGNITE strategy and productivity initiatives bode well.
Beyond Meat (NASDAQ: BYND), the bellwether alternative-protein stock, lost a little weight on the stock market Wednesday. The first note was a reiteration, with Piper Sandler prognosticator Michael Lavery leaving unchanged his neutral recommendation and $64 price target on Beyond Meat stock. In his latest note on the company, Lavery waxed enthusiastic about the prospects of the McPlant, the Beyond Meat-developed sandwich being tested as a menu item by McDonald's. Pointing out that the McPlant will be rolled out in a new phase to around 600 McDonald's restaurants in California and Texas next month, he wrote that this "suggests a full U.S. launch to nearly 14,000 restaurants is likely coming later than the end of 1Q."